137 related articles for article (PubMed ID: 33299824)
21. Lung Shunt Fraction prior to Yttrium-90 Radioembolization Predicts Survival in Patients with Neuroendocrine Liver Metastases: Single-Center Prospective Analysis.
Ludwig JM; Ambinder EM; Ghodadra A; Xing M; Prajapati HJ; Kim HS
Cardiovasc Intervent Radiol; 2016 Jul; 39(7):1007-14. PubMed ID: 26964779
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of ADC measurements in predicting overall survival in patients undergoing
Alis D; Durmaz ESM; Gulsen F; Bas A; Kabasakal L; Sager S; Numan F
Clin Imaging; 2019; 57():124-130. PubMed ID: 31220677
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
[TBL] [Abstract][Full Text] [Related]
24. Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors.
Michl M; Haug AR; Jakobs TF; Paprottka P; Hoffmann RT; Bartenstein P; Boeck S; Haas M; Laubender RP; Heinemann V
Oncology; 2014; 86(1):24-32. PubMed ID: 24401529
[TBL] [Abstract][Full Text] [Related]
25. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases.
Cao CQ; Yan TD; Bester L; Liauw W; Morris DL
Br J Surg; 2010 Apr; 97(4):537-43. PubMed ID: 20205229
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver.
Su YK; Mackey RV; Riaz A; Gates VL; Benson AB; Miller FH; Yaghmai V; Gabr A; Salem R; Lewandowski RJ
J Vasc Interv Radiol; 2017 Nov; 28(11):1520-1526. PubMed ID: 28673658
[TBL] [Abstract][Full Text] [Related]
27. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
[TBL] [Abstract][Full Text] [Related]
28. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
[TBL] [Abstract][Full Text] [Related]
29. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival.
Sato KT; Lewandowski RJ; Mulcahy MF; Atassi B; Ryu RK; Gates VL; Nemcek AA; Barakat O; Benson A; Mandal R; Talamonti M; Wong CY; Miller FH; Newman SB; Shaw JM; Thurston KG; Omary RA; Salem R
Radiology; 2008 May; 247(2):507-15. PubMed ID: 18349311
[TBL] [Abstract][Full Text] [Related]
30. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.
Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H
J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059
[TBL] [Abstract][Full Text] [Related]
31. Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis.
Kim AY; Frantz S; Brower J; Akhter N
J Vasc Interv Radiol; 2019 Mar; 30(3):298-304.e2. PubMed ID: 30819469
[TBL] [Abstract][Full Text] [Related]
32. Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization.
Levey AO; Elsayed M; Lawson DH; Ermentrout RM; Kudchadkar RR; Bercu ZL; Yushak ML; Newsome J; Kokabi N
Cardiovasc Intervent Radiol; 2020 Feb; 43(2):254-263. PubMed ID: 31686137
[TBL] [Abstract][Full Text] [Related]
33. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW
JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of radiolabelled somatostatin analogues (
Medina-Ornelas SS; García-Pérez FO
Rev Esp Med Nucl Imagen Mol; 2017; 36(3):166-174. PubMed ID: 27890514
[TBL] [Abstract][Full Text] [Related]
35. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.
Citterio D; Pusceddu S; Facciorusso A; Coppa J; Milione M; Buzzoni R; Bongini M; deBraud F; Mazzaferro V
Eur J Surg Oncol; 2017 Feb; 43(2):380-387. PubMed ID: 27956320
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
[TBL] [Abstract][Full Text] [Related]
37. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases.
Peker A; Çiçek O; Soydal Ç; Küçük NÖ; Bilgiç S
Diagn Interv Radiol; 2015; 21(1):54-9. PubMed ID: 25430526
[TBL] [Abstract][Full Text] [Related]
38. Yttrium-90 Radioembolization as Salvage Therapy for Liver Metastases From Colorectal Cancer.
Kalva SP; Rana RS; Liu R; Rachamreddy N; Dave B; Sharma A; Ganguli S; Rabito C; Kwak E; Blaszkowsky LS
Am J Clin Oncol; 2017 Jun; 40(3):288-293. PubMed ID: 25374143
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Radioembolization in Patients with Chemorefractory Colorectal Cancer Liver Metastasis: a Single-Center Experience.
Türk G; Eldem G; Kılıçkap S; Bozkurt FM; Salancı BV; Çil BE; Peynircioğlu B; Yalçın Ş; Balkancı F
J Gastrointest Cancer; 2019 Jun; 50(2):236-243. PubMed ID: 29354877
[TBL] [Abstract][Full Text] [Related]
40. 90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival.
Xing M; Lahti S; Kokabi N; Schuster DM; Camacho JC; Kim HS
Clin Nucl Med; 2016 Jan; 41(1):21-7. PubMed ID: 26222534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
